Clinical Read2026-06-01

RETEVMO (Selpercatinib) - (LIBRETTO-432)

Name: RETEVMO (Selpercatinib) - (LIBRETTO-432)
Start: 2026-06-01

Eli Lilly and CompanyLLY

Indication: Early-stage (II-IIIA) rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC).
Stage: phase3
Event: Phase 3